Evaluating the Effectiveness of Lacrimal Gland Botulinum Toxin Using the TEARS Score

Ophthalmic Plast Reconstr Surg. 2024 Mar-Apr;40(2):192-197. doi: 10.1097/IOP.0000000000002532. Epub 2024 Mar 1.

Abstract

Purpose: Botulinum toxin (BoNTA) lacrimal gland injections are one treatment option for managing epiphora. Outcomes for epiphora in existing studies are subjective and lack grading. This study utilized validated grading instruments to evaluate the efficacy of BoNTA lacrimal gland injections.

Methods: Prospective study evaluating the TEARS score and quality of life in patients receiving incobotulinum toxin (Xeomin) lacrimal gland injections for epiphora. Epiphora was graded using the TEARS score. Quality of life was evaluated using the watery eye quality of life score. Etiology, benefit duration, complications and additional injections were recorded.

Results: Of the 28 patients, (median age 67.5 years), 19 (68%) had facial palsy gustatory epiphora (GE). Median effect duration was 13 weeks. Improvements in tearing frequency (T), clinical effects (E), and activity limitation (A) were seen in 57%, 57%, and 71% of patients, respectively. Median watery eye quality of life score improved from 42.4/100 ± 10.1 to 10.6 ± 15.5 (p < 0.001). Alongside crocodile tears, reflex tearing R-scores improved in 68% of patients with GE vs. 11% with non-GE causes (p = 0.004618). In total 89% of patients with GE and 56% with non-GE requested repeat injections. Self-reported percentage improvement ranged from 0% to 100% (median 60%, interquartile range 10%-76.25%).

Conclusions: This is the first study reporting the outcomes of BoNTA lacrimal gland injections using validated TEARS and watery eye quality of life scores. Clinical and quality of life improvements are seen in most patients. Patients with GE achieve an additional improvement in dry eye-related reflex tearing alongside crocodile tears which both improve with BoNTA. TEARS data supports using BoNTA in these patients and is a useful validated grading instrument for epiphora.

MeSH terms

  • Aged
  • Botulinum Toxins, Type A* / therapeutic use
  • Humans
  • Lacrimal Apparatus Diseases* / diagnosis
  • Lacrimal Apparatus Diseases* / drug therapy
  • Lacrimal Apparatus Diseases* / etiology
  • Lacrimal Apparatus*
  • Neuromuscular Agents* / therapeutic use
  • Prospective Studies
  • Quality of Life
  • Tears

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A